Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZW) Asset Writedowns and Impairment (2022 - 2025)

Core Scientific (CORZW) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • Quarterly Asset Writedowns and Impairment rose 111.68% to $11.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$85.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $11.4 million for FY2025, N/A changed from the prior year.
  • Asset Writedowns and Impairment hit $11.4 million in Q4 2025 for Core Scientific, up from -$97.3 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $790.8 million in Q2 2022 to a low of -$784.8 million in Q3 2022.
  • Historically, Asset Writedowns and Impairment has averaged $3.4 million across 3 years, with a median of $7.2 million in 2022.
  • Biggest YoY gain for Asset Writedowns and Impairment was 111.68% in 2025; the steepest drop was 111.68% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $3.1 million in 2022, then tumbled by 3277.43% to -$97.3 million in 2024, then soared by 111.68% to $11.4 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for CORZW at $11.4 million in Q4 2025, -$97.3 million in Q4 2024, and $97.3 million in Q2 2024.